frenzy, page-15

re: sirtex goal: $5 then $8 -$9 I agree with the Huntleys who are very conservative and Hunter hall and the Bioshares recommend buy at this level . The consolidation from 3.15 to this level is to be expected from daytraders ,and sellers who may have bought at 5 or 6 when Cephalon made the bid. This is a huge mistake to sell.If I owned 5 dollars stock and I was this patient for the last two years I would be gratefeul for the opportunity to buy more shares under $3 now. AT an avg of 3+5 = $8/$2= $4 price this is where those who buy more at this level will soon see prices towards $5 and be in the black. The sales and profit momentum is just at the beginning of the growth curve since there are many avenues of new revenue and profit growth coming: Australian reimbursement is already a given, US center growth is at 62 now compared to 24 last year which had only revenue of 2 million for last years March quarter and for which this year's March quarter is going to be a huge amount stronger, US center growth is growing at a more rapid rate as acceptance of the product is growing, also new symposium are training more physicians to admiister Sir Spheres which drectly leads to more growth,European reimbursement is coming as indicated at the meeting , indications for the Sir Spheres are expanding as clinical trials data is showing success in treating different types of cancer that have metastasized to the liver whch is a huge potential market. AS the estimate without any of these in Bioshares is 72 cents for 2008, if these are factored in it could be a lot higher than even a $1.25 a share in earnings. Even considering the 72 cent estimate this is P.E of 4 for a company growing over 100%+. Considering Genentech has a eps estimate of 1.50 for 2008 and sells near $90 with projected 30% growth rate USD, Genentech has a P.E/ growth rate =60/30= 2 and Sirtex has a P.E./growth rate of of 4/100 of = .04. This means that in relative terms Genentech is 2/.04= 50 times as expensive as Sirtex. In other words Sirtex is exceedingly undervalued and you are paying nothing for a very high growth rate for Sirtex.This also means I am using my funds from gold and oill shares redemptions and taking advantage of the recent consolidation of Sirtex to add to my shares. DR Gray owns 17million shares or 47 million dollars of his net worth and I am very comfortable investing my hard earned funds with him as he will do the best for the shareholders and get the value for himself and us shareholders.I believe that after the $5 mark is passed he will be listening to the expressed interest of Pfizer and Sanofi as it would be cheaper for them to buy Sirtex for 8 or 9 now since it takes over 10 years and 500 million USD to develop a treatment like Sir Spheres. Also Genentech and Bristol Myers are interested as they are beginning trials with Avastin and Sir Spheres. Also Mayne has a interest in acquiring oncology companies as these drug treatments like Sir Spheres are very high margined and profitable at $ 15,000USD per treatment and Sitex is treating only 0.5 % of the eligible poplation at a large profit and Sirtex has a very high gross margin of 85 % and Mayne has the funds as they recently divested themselves of their low margined hospital division. They also are an Australian hospital and this would be puttting together two high growth companies. THis is my opinion after being aligned in the industry a very long time .Do your ownwork although I am glad if I enlightened anyone to what is really going on.